Updates in new antiplatelet therapies, new patient populations for PCI and AI to guide CAD staging were among the top ...

Both regimens “can be considered standard chemotherapy options” for high-risk, HR-positive early breast cancer, said Sherko Kuemmel, MD, PhD.

CARE Pharmacies appointed Ryan Hollingsworth, Natalie Ryan and Steven Pieri to its 2025 board of directors, and Lionel ...

Jefferies analyst Stephen Barker maintained a Buy rating on Daiichi Sankyo Company (DSKYF – Research Report) on January 19 and set a price ...

Risk for bleeding events is significantly affected by DOAC score in patients with atrial fibrillation who have received TAVR.

Plus: Moderna’s bird flu vaccine, Obamacare enrollment breaks records, and AstraZeneca’s new breast cancer treatment is FDA ...

The FDA has approved a new treatment for patients with a common form of breast cancer that has spread to other parts of the body or cannot be surgically removed.

Researchers from Mass General Brigham evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the ...

The FDA approved datopotamab deruxtecan-dlnk for treatment of certain patients with advanced breast cancer.The indication ...

Even before the FDA's recent approval of Dato-DXd in breast cancer, analysts predicted sales of the antibody-drug conjugate ...

DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.

Marking the second global approval after Japan, the U.S. FDA has approved Datroway (datopotamab deruxtecan), a trophoblast cell surface antigen 2-directed antibody-drug conjugate (ADC) from Daiichi ...